Transcription of Reversing the New Anticoagulants - UCSF Medical Education
{{id}} {{{paragraph}}}
Example: bachelor of science
Reversing the New Anticoagulants - UCSF Medical Education
11/6/20131 Reversing the New AnticoagulantsSusan C. Lambe, MDAssistant Clinical ProfessorDepartment of Emergency MedicineUniversity of California, San FranciscoDisclosureRoadmap for today11/6/20132 Roadmap for today Characteristics of novel Anticoagulants Approach to the bleeding patient Specific reversal agents ucsf guidelinesScope of Problem Prevalence atrial fibrillation million in 2005 million by 2050 VTE = 900K/yr in US 1-2% of adults take warfarinWarfarin1920s Outbreak hemorrhagic disease in cattle in northern US and Canada1933 Isolated by Karl Link1948 Rodenticde1954 Approved in humansWARF-arinWisconsin Alumni Research FoundationCoumarin, plant molecule in sweet clover11/6/20133 Warfarin Disadvantages Bridging Drug and food interactions Long half-life Close monitoring requiredWhy New Anticoagulants ?
11/6/2013 2 Roadmap for today • Characteristics of novel anticoagulants • Approach to the bleeding patient • Specific reversal agents • UCSF guidelines Scope of Problem • Prevalence atrial fibrillation • 3.03 million in 2005 • 7.56 million by 2050 • VTE = 900K/yr in US • 1-2% of adults take warfarin Warfarin 1920s –Outbreak hemorrhagic disease in cattle in
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: